CDK (cyclin-dependent kinase) inhibitor

systematic review meta-analysis network meta-analysis

Select advanced breast cancer (metastatic)lung cancer (metastatic) All type of patientHR+ HER2 -       CDK4 and CDK6 selective CDK inhibitorCDK4/6 inhibitor abemaciclib ribociclib palbociclib vs endocrine therapy alone       1st line2nd lineHER-2 negativeHR positivepostmenopausal

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (10) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)
advanced breast cancer (metastatic)
abemaciclib
MONARCH 3, 2017        NCT	Abemaciclib +nsAI	nsAI		1st line HER-2 negative HR positive postmenopausal	Low risk of bias	conclusive
palbociclib
PALOMA 3, 2015            NCT	palbociclib + fulvestrant	fulvestrant alone	2nd line	2nd line HER-2 negative HR positive	Low risk of bias	conclusive
PALOMA-2, 2016      NCT	palbociclib + letrozole	letrozole alone	first line	1st line HER-2 negative HR positive postmenopausal	Low risk of bias	conclusive
PALOMA 1/TRIO-18, 2015      NCT	palbociclib + letrozole	letrozole alone		1st line HER-2 negative HR positive postmenopausal	Exploratory	suggesting
ribociclib
MONALEESA-2, 2016        NCT	ribociclib (LEE011) + letrozole	letrozole alone	first line	1st line HER-2 negative HR positive postmenopausal	Low risk of bias	conclusive
lung cancer (metastatic)
abemaciclib
JUNIPER, 2018      NCT	abemaciclib	erlotinib	2nd line		Risk of bias	remark